DE69630215D1 - Diltiazem-formulierung mit gesteuerter freigabe - Google Patents

Diltiazem-formulierung mit gesteuerter freigabe

Info

Publication number
DE69630215D1
DE69630215D1 DE69630215T DE69630215T DE69630215D1 DE 69630215 D1 DE69630215 D1 DE 69630215D1 DE 69630215 T DE69630215 T DE 69630215T DE 69630215 T DE69630215 T DE 69630215T DE 69630215 D1 DE69630215 D1 DE 69630215D1
Authority
DE
Germany
Prior art keywords
diltiazem
polymeric
layer
coated
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69630215T
Other languages
English (en)
Other versions
DE69630215T2 (de
Inventor
Chih-Ming Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Andrx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals LLC filed Critical Andrx Pharmaceuticals LLC
Application granted granted Critical
Publication of DE69630215D1 publication Critical patent/DE69630215D1/de
Publication of DE69630215T2 publication Critical patent/DE69630215T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69630215T 1995-03-24 1996-03-13 Diltiazem-formulierung mit gesteuerter freigabe Expired - Lifetime DE69630215T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US409449 1995-03-24
US08/409,449 US5567441A (en) 1995-03-24 1995-03-24 Diltiazem controlled release formulation
PCT/US1996/003399 WO1996029992A1 (en) 1995-03-24 1996-03-13 Diltiazem controlled release formulation

Publications (2)

Publication Number Publication Date
DE69630215D1 true DE69630215D1 (de) 2003-11-06
DE69630215T2 DE69630215T2 (de) 2004-07-15

Family

ID=23620543

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69630215T Expired - Lifetime DE69630215T2 (de) 1995-03-24 1996-03-13 Diltiazem-formulierung mit gesteuerter freigabe

Country Status (11)

Country Link
US (2) US5567441A (de)
EP (1) EP0814780B1 (de)
JP (1) JP4381479B2 (de)
CN (1) CN1185104A (de)
AT (1) ATE250927T1 (de)
AU (1) AU697164B2 (de)
CA (1) CA2215378C (de)
DE (1) DE69630215T2 (de)
NZ (1) NZ305594A (de)
TW (1) TW404841B (de)
WO (1) WO1996029992A1 (de)

Families Citing this family (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5871776A (en) * 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
US5671345A (en) * 1995-06-06 1997-09-23 Apple Computer, Inc. System and method for intercepting and reconstructing graphics management tool marking instructions
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
US5914134A (en) * 1997-01-27 1999-06-22 Wockhardt Europe Limited Process for the pulsatile delivery of diltiazem HCL and product produced thereby
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
FR2778848B1 (fr) * 1998-05-20 2001-11-23 Prographarm Lab Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation
US6524620B2 (en) * 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
ES2157731B1 (es) * 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
SI1105105T1 (sl) * 1998-08-12 2006-08-31 Altana Pharma Ag Oralna dajalna oblika za piridin-2-ilmetilsulfinil-1J-benzimidazole
SE9803871D0 (sv) * 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
ID29852A (id) * 1998-11-02 2001-10-18 Elan Corp Plc Cs Komposisi pelepasan modifikasi multi partikulasi
US20090149479A1 (en) * 1998-11-02 2009-06-11 Elan Pharma International Limited Dosing regimen
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6039979A (en) * 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
AU764453B2 (en) 1999-10-29 2003-08-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
CZ304671B6 (cs) 1999-11-11 2014-08-27 Pharmacia Ab Farmaceutický prostředek obsahující tolterodin a jeho použití
US7108866B1 (en) 1999-12-10 2006-09-19 Biovall Laboratories International Srl Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) * 1999-12-10 2006-07-13 Biovail Laboratories International S.R.L. Chronotherapeutic diltiazem formulations and the administration thereof
US20040185099A1 (en) * 2000-01-20 2004-09-23 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6623757B2 (en) 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Antibiotic composition
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6632453B2 (en) 2000-02-24 2003-10-14 Advancis Pharmaceutical Corp. Ciprofoxacin-metronidazole antibiotic composition
US6730320B2 (en) 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6627222B2 (en) 2000-02-24 2003-09-30 Advancis Pharmaceutical Corp. Amoxicillin-dicloxacillin antibiotic composition
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
US6663891B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Erythromyacin antibiotic product, use and formulation thereof
US6638532B2 (en) 2000-02-24 2003-10-28 Advancis Pharmaceutical Corp. Tetracycline—doxycycline antibiotic composition
US6669948B2 (en) 2000-02-24 2003-12-30 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6663890B2 (en) 2000-02-24 2003-12-16 Advancis Pharmaceutical Corp. Metronidazole antibiotic product, use and formulation thereof
US6610328B2 (en) 2000-02-24 2003-08-26 Advancis Pharmaceutical Corp. Amoxicillin-clarithromycin antibiotic composition
US6667057B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Levofloxacin antibiotic product, use and formulation thereof
US6623758B2 (en) 2000-02-24 2003-09-23 Advancis Pharmaceutical Corp. Cephalosporin-metronidazole antibiotic composition
US6667042B2 (en) 2000-02-24 2003-12-23 Advancis Pharmaceutical Corp. Fluroquinilone antibiotic product, use and formulation thereof
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6419954B1 (en) * 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US6984402B2 (en) * 2000-10-03 2006-01-10 Elite Laboratories, Inc. Chrono delivery formulations and method of treating atrial fibrillation
US7105174B2 (en) * 2000-10-13 2006-09-12 Advancis Pharmaceutical Corporation Multiple-delayed release anti-neoplastic product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US7157095B2 (en) * 2000-10-13 2007-01-02 Advancis Pharmaceutical Corporation Multiple-delayed release antifungal product, use and formulation thereof
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
CN101317825A (zh) 2000-10-30 2008-12-10 欧罗赛铁克股份有限公司 控释氢可酮制剂
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US6635675B2 (en) 2001-11-05 2003-10-21 Cypress Bioscience, Inc. Method of treating chronic fatigue syndrome
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
US20030091633A1 (en) * 2001-11-15 2003-05-15 John Kelly Methods and compositions for use of (S)-bisoprolol
US20030118652A1 (en) * 2001-11-15 2003-06-26 John Kelly Methods and compositions for use of (S)-bisoprolol
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
US6663888B2 (en) * 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US20050025824A1 (en) * 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
WO2005046457A2 (en) * 2003-11-05 2005-05-26 Texas Scottish Rite Hospital For Children A biomimetic biosynthetic nerve implant
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
KR20050088079A (ko) 2002-11-15 2005-09-01 이데닉스 (케이만) 리미티드 2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
JP2006510655A (ja) * 2002-12-11 2006-03-30 ファイザー・プロダクツ・インク 高脂肪環境への活性物質の制御放出
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
US8367111B2 (en) 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258944B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2533178C (en) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1653925A1 (de) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robustes pellet
JP2007502294A (ja) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1728512A1 (de) * 2004-03-26 2006-12-06 Eisai R&D Management Co., Ltd. Kontrolliert laugende zubereitung und herstellungsverfahren dafür
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
WO2006004774A2 (en) * 2004-06-28 2006-01-12 Stanford University Laulimalide analogues as therapeutic agents
EP1771158A4 (de) 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp Tablette für pulsierte abgabe
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
NZ728442A (en) 2004-10-21 2018-05-25 Adare Pharmaceuticals Inc Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060121112A1 (en) * 2004-12-08 2006-06-08 Elan Corporation, Plc Topiramate pharmaceutical composition
EP1830648A4 (de) * 2004-12-09 2008-03-12 Celgene Corp Behandlung mit d-threo-methylphenidat
EA200702221A1 (ru) * 2005-04-12 2008-04-28 Элан Фарма Интернэшнл Лимитед Композиции с контролируемым высвобождением для лечения бактериальной инфекции, содержащие цефалоспорин
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
EP1933852B1 (de) 2005-09-27 2018-12-19 TissueTech, Inc. Amnion-zubereitungen und gereinigte zusammensetzungen und anwendungsverfahren
US8187639B2 (en) * 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US7994220B2 (en) 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20090148519A1 (en) * 2005-09-29 2009-06-11 Yasuhiro Zaima Pulsed-release preparation having improved disintegration properties in vivo
US8440695B2 (en) * 2005-11-09 2013-05-14 St Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MX2008006888A (es) 2005-11-28 2008-09-30 Marinus Pharmaceuticals Formulas y metodos para la manufactura y uso de la ganaxolona.
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
CN102887900B (zh) 2006-09-22 2015-04-29 药品循环公司 布鲁顿酪氨酸激酶的抑制剂
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
ES2529147T3 (es) 2006-12-26 2015-02-17 Pharmacyclics, Inc. Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
CA2699157A1 (en) 2007-09-10 2009-03-19 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
MX2011001384A (es) 2008-08-06 2011-09-27 Gosforth Ct Holdings Pty Ltd Composiciones y metodos para tratar trastornos psiquiatricos.
AU2009288245B2 (en) 2008-08-27 2012-12-20 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20100158905A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy of arthritis with tranilast
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
CA2758571A1 (en) 2009-04-24 2010-10-28 Tissuetech, Inc. Compositions containing hc-ha complex and methods of use thereof
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
MX2012006240A (es) 2009-12-02 2012-10-03 Aptalis Pharma Ltd Microcapsulas de fexofenadina y composiciones que contienen las mismas.
ES2602475T3 (es) 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
AU2011248877B9 (en) 2010-04-27 2015-11-05 Calcimedica Inc. Compounds that modulate intracellular calcium
EP2563759B1 (de) 2010-04-27 2022-04-06 Calcimedica, Inc. Verbindungen als modulatoren von intrazellulärem calcium
EP2568999B1 (de) 2010-05-11 2018-07-11 Mallinckrodt Ard Ip Limited Acth zur behandlung von amyotropher lateralsklerose
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
ES2822301T3 (es) 2011-06-10 2021-04-30 Tissuetech Inc Métodos de procesamiento de tejidos de soporte fetal
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
ITFI20110172A1 (it) 2011-08-08 2013-02-09 Valpharma Sa Formulazione multiparticolata a rilascio modificato di diltiazem hcl.
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
AU2012345732B2 (en) 2011-11-30 2016-07-14 Emory University Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
EP3838293A1 (de) 2012-07-11 2021-06-23 Tissuetech, Inc. Zusammensetzungen mit hc-ha/ptx3-komplexen und verfahren zur verwendung davon
WO2014052914A1 (en) 2012-09-28 2014-04-03 University Of Washington Through Its Center For Commercialization Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
US10232018B2 (en) 2013-03-14 2019-03-19 Mallinckrodt Ard Ip Limited ACTH for treatment of acute respiratory distress syndrome
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20150133516A1 (en) 2013-11-13 2015-05-14 Brian K. Adams Methods and Compositions for Treating ADHD
AU2014360446A1 (en) 2013-12-05 2016-06-09 Pharmacyclics, Llc Inhibitors of Bruton's tyrosine kinase
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US9493482B2 (en) 2015-02-06 2016-11-15 University Of Washington Compounds and methods for preventing or treating sensory hair cell death
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
TW201642914A (zh) 2015-02-23 2016-12-16 組織科技股份有限公司 用於治療眼部疾病及失調的裝置及方法
MX2017011018A (es) 2015-02-27 2018-01-18 Curtana Pharmaceuticals Inc Inhibicion de la actividad de olig2.
TWI720984B (zh) 2015-05-20 2021-03-11 美商帝聖工業公司 用於防止上皮細胞增生及上皮-間質轉移之組合物及方法
AU2016288643A1 (en) 2015-07-02 2018-02-22 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for delivery of miRNA and methods for treatment of cancer
ES2952064T3 (es) 2015-12-16 2023-10-26 Walter & Eliza Hall Inst Medical Res Inhibición de la proteína SH2 inducida por citocinas en células NK
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10821105B2 (en) 2016-05-25 2020-11-03 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
KR102605329B1 (ko) 2016-08-26 2023-11-22 커타나 파마슈티칼스, 인크. Olig2 활성의 억제
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
CN112739345A (zh) 2017-11-06 2021-04-30 斯奈普生物公司 Pim激酶抑制剂组合物，方法和其用途
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
CA3107433A1 (en) 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic trpv1 agonists
EP3906026A4 (de) 2018-12-31 2022-10-19 Biomea Fusion, LLC Irreversible inhibitoren der menin-mll-interaktion
MX2021011081A (es) 2019-03-15 2022-01-18 Unicycive Therapeutics Inc Derivados de nicorandil.
US11638904B2 (en) * 2019-12-16 2023-05-02 The University Of South Alabama Porous membrane encapsulated pellet and method for its preparation
EP4263542A1 (de) 2020-12-16 2023-10-25 Biomea Fusion, Inc. Kondensierte pyrimidinverbindungen als inhibitoren der menin-mll-interaktion
CA3204457A1 (en) 2021-01-06 2022-07-14 Ben SESSA Mdma in the treatment of alcohol use disorder
US20240190809A1 (en) 2021-05-11 2024-06-13 Awakn Ls Europe Holdings Limited Therapeutic aminoindane compounds and compositions
AU2022283967A1 (en) 2021-06-03 2024-01-18 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
TW202320796A (zh) 2021-08-11 2023-06-01 美商拜歐米富士恩股份有限公司 用於糖尿病的menin-mll相互作用之共價抑制劑
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
EP4370506A1 (de) 2021-12-30 2024-05-22 Biomea Fusion, Inc. Pyrazinverbindungen als flt3-hemmer
CN114129541B (zh) * 2022-01-05 2023-05-30 南通联亚药业股份有限公司 一种盐酸地尔硫卓缓释胶囊及其制备方法和应用
WO2023139163A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-benzodioxole esters and their therapeutic use
WO2023156565A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
US5002776A (en) * 1983-12-22 1991-03-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
US4917899A (en) * 1983-12-22 1990-04-17 Elan Corporation Plc Controlled absorption diltiazem formulation
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
IT1188212B (it) * 1985-12-20 1988-01-07 Paolo Colombo Sistema per il rilascio a velocita' controllata di sostanze attive
IT1200217B (it) * 1986-09-30 1989-01-05 Valducci Roberto Membrana per uso farmaceutico ed industriale
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
DK173505B1 (da) * 1987-02-20 2001-01-15 Pharmatec Internat S R L Fremgangsmåde til fremstilling af en diltiazempellet med langsom afgivelse og anvendelse af således fremstillede pelleter t
DE3856555T2 (de) * 1987-10-16 2004-04-29 Elan Corp. Plc Diltiazem-Zusammensetzungen mit kontrollierter Wirkstoffabsorption
US5336504A (en) * 1987-10-16 1994-08-09 Elan Corporation, Plc Diltiazem formulations and methods of treatment
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
FR2624732B1 (fr) * 1987-12-21 1991-02-15 Synthelabo Formulation pharmaceutique a liberation prolongee
DE3922167A1 (de) * 1988-04-16 1991-01-17 Sanol Arznei Schwarz Gmbh Oral zu verabreichende diltiazemhydrochlorid enthaltende pharmazeutische zubereitung zur einmal taeglichen applikation und verfahren zu deren herstellung
US5472710A (en) * 1988-04-16 1995-12-05 Schwarz Pharma Ag Pharmaceutical preparation to be administered orally with controlled release of active substance and method for its manufacture
US5344657A (en) * 1988-04-27 1994-09-06 Elf Sanofi Microbeads of diltiazem, a process for their manufacture and a substained-release pharmaceutical composition containing them
ES2077023T3 (es) * 1989-03-10 1995-11-16 Yamanouchi Pharma Co Ltd Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada.
JP2558396B2 (ja) * 1990-06-28 1996-11-27 田辺製薬株式会社 放出制御型製剤
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5260068A (en) * 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5260069A (en) * 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5376384A (en) * 1992-12-23 1994-12-27 Kinaform Technology, Inc. Delayed, sustained-release pharmaceutical preparation
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
NZ270078A (en) * 1994-12-06 1998-05-27 Bernard Charles Sherman Diltiazem hydrochloride formulation comprising beads with immediate, intermediate, and delayed release dissolution profiles

Also Published As

Publication number Publication date
US5567441A (en) 1996-10-22
CA2215378C (en) 2008-09-16
DE69630215T2 (de) 2004-07-15
US5834023A (en) 1998-11-10
WO1996029992A1 (en) 1996-10-03
EP0814780A4 (de) 2000-03-15
ATE250927T1 (de) 2003-10-15
JP4381479B2 (ja) 2009-12-09
EP0814780B1 (de) 2003-10-01
AU5363196A (en) 1996-10-16
EP0814780A1 (de) 1998-01-07
TW404841B (en) 2000-09-11
JPH11502843A (ja) 1999-03-09
CA2215378A1 (en) 1996-10-03
NZ305594A (en) 1998-12-23
CN1185104A (zh) 1998-06-17
AU697164B2 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
ATE250927T1 (de) Diltiazem-formulierung mit gesteuerter freigabe
NZ511448A (en) A dosage form of diltiazem that exhibits a release rate profile corresponding to a "two peak" plasma level profile in vivo
KR920000313A (ko) 제어성 약학 제제
EA200100538A1 (ru) Новая гранула с контролируемым высвобождением, способ ее изготовления и включающая ее композиция из множества единиц
NO178136C (no) Framgangsmåte for framstilling av et preparat for styrt frigjöring av en farmasöytisk aktiv substans
AU5795896A (en) Controlling the porosity and permeation of a web
TR200001021T2 (tr) Aktif maddelerin kontrollü salınması için biyo aşındırılabilir makromerler.
NO872499D0 (no) Fremgangsmaate for behandling av et biologisk aktivt stoff.
EP0213083A3 (de) Tablette mit gesteuerter Wirkstoffabgabe
AU9045182A (en) Latex graft copolymer containing aldehyde realtive with biological agents
BR9806174A (pt) Péletes tendo um núcleo revestido com um antifúngico e um polìmero
DE3278263D1 (en) Composition for coating food and drugs, and granules so coated
EP0602617A3 (de) Superabsorbierende Strukturen
AU7772291A (en) Method and device for making living cells permeable
ATE87201T1 (de) Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung.
NO973950L (no) Peroral sammensetning for kontrollert frigjöring i nedre gastrointestinaltrakt
DE69221711T2 (de) Verabreichungsvorrichtung von Wirkstoffdispersionen mit kontrollierter Freisetzung
NO981630D0 (no) Nye 5-O-desosaminyl-6-O-metylerytronolid A-derivater, fremstillingsmetode derfor og anvendelse derav for fremstilling av biologisk aktive materialer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition